 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
20 April 1999 | Volume 130 Issue 8 | Pages 625-636
Background: Physicians managing patients with nonvalvular atrial fibrillation must consider the risks, benefits, and costs of treatments designed to restore and maintain sinus rhythm compared with those of rate control with antithrombotic prophylaxis.
Objective: To compare the cost-effectiveness of cardioversion, with or without antiarrhythmic agents, with that of rate control plus warfarin or aspirin.
Design: A Markov decision-analytic model was designed to simulate long-term health and economic outcomes.
Data Sources: Published literature and hospital accounting information.
Target Population: Hypothetical cohort of 70-year-old patients with different baseline risks for stroke.
Time Horizon: 3 months.
Perspective: Societal.
Intervention: Therapeutic strategies using different combinations of cardioversion alone, cardioversion plus amiodarone or quinidine therapy, and rate control with antithrombotic treatment.
Outcome Measures: Expected costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness.
Results of Base-Case Analysis: Strategies involving cardioversion alone were more effective and less costly than those not involving this option. For patients at high risk for ischemic stroke (5.3% per year), cardioversion alone followed by repeated cardioversion plus amiodarone therapy on relapse was most cost-effective ($9300 per QALY) compared with cardioversion alone followed by warfarin therapy on relapse. This strategy was also preferred for the moderate-risk cohort (3.6% per year), but the benefit was more expensive ($18 900 per QALY). In the lowest-risk cohort (1.6% per year), cardioversion alone followed by aspirin therapy on relapse was optimal.
Results of Sensitivity Analysis: The choice of optimal strategy and incremental cost-effectiveness was substantially influenced by the baseline risk for stroke, rate of stroke in sinus rhythm, efficacy of warfarin, and costs and utilities for long-term warfarin and amiodarone therapy.
Conclusions: Cardioversion alone should be the initial management strategy for persistent nonvalvular atrial fibrillation. On relapse of arrhythmia, repeated cardioversion plus low-dose amiodarone is cost-effective for patients at moderate to high risk for ischemic stroke.
Author and Article Information
From Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Dartmouth Medical School, Hanover, New Hampshire; and Veterans Affairs Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, Vermont.
Acknowledgments: The authors thank Dennis L. Disch, MD, for assistance with the development of the original Markov model on which this work was based.
Requests for Reprints: Edward Catherwood, MD, MS, Cardiology Division, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756-0001.
Current Author Addresses: Drs. Catherwood, Holzberger, Greenberg, Gerling, and Malenka: Cardiology Division, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756-0001.
Dr. Fitzpatrick: Northeast Cardiology Associates, 1360 Wyoming Avenue, Scranton, PA 18509.
Dr. Birkmeyer: Department of Surgery, Department of Veterans Affairs Medical Center, White River Junction, VT 05009. ARTICLE
Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  P. S. Chan, S. Vijan, F. Morady, and H. Oral Cost-Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2513 - 2520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Marshall, A. R. Levy, H. Vidaillet, E. Fenwick, A. Slee, G. Blackhouse, H. L. Greene, D. G. Wyse, G. Nichol, B. J. O'Brien, et al. Cost-Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation Ann Intern Med, November 2, 2004; 141(9): 653 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Hagens, K. M. Vermeulen, E. M. TenVergert, D. J. Van Veldhuisen, H. A. Bosker, O. Kamp, J. H. Kingma, J. G.P. Tijssen, H. J.G.M. Crijns, I. C. Van Gelder, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation -- results from the RAte Control versus Electrical cardioversion (RACE) study Eur. Heart J., September 1, 2004; 25(17): 1542 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Khairy and S. Nattel New insights into the mechanisms and management of atrial fibrillation Can. Med. Assoc. J., October 29, 2002; 167(9): 1012 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Krahn, G. Klein, A.C. Skanes, and R. Yee Amiodarone: pearl or peril? Eur. Heart J., July 1, 2002; 23(13): 1001 - 1002. [Full Text] [PDF]
|
|
|
|
|
|
G.B Lumer, D Roy, M Talajic, A Couturier, J Lambert, N Frasure-Smith, B Thibault, M Dubuc, P Gagne, and S Nattel Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Eur. Heart J., July 1, 2002; 23(13): 1050 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Nichol, F McAlister, B Pham, A Laupacis, B Shea, M Green, A Tang, and G Wells Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation Heart, June 1, 2002; 87(6): 535 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Galperin, M. V. Elizari, P. A. Chiale, R. T. Molina, R. Ledesma, A. O. Scapin, and M. V. Blanco Efficacy of Amiodarone for the Termination of Chronic Atrial Fibrillation and Maintenance of Normal Sinus Rhythm: A Prospective, Multicenter, Randomized, Controlled, Double Blind Trial Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 341 - 350. [Abstract] [PDF]
|
|
|
|
 |
|
 T. O. Tengs, M. Yu, E. Luistro, and H. B. Bosworth Health-Related Quality of Life After Stroke A Comprehensive Review Editorial Comment : Health-Related Quality Of Life After Stroke: A Comprehensive Review Stroke, April 1, 2001; 32(4): 964 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Oral, B. P. Knight, C. Sticherling, M. H. Kim, R. L. Baker, S. P. Chough, K. Wasmer, F. Pelosi JR, G. F. Michaud, A. M. Fendrick, et al. Cost Analysis of Transthoracic Cardioversion of Atrial Fibrillation With and Without Ibutilide Pretreatment Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 259 - 266. [Abstract] [PDF]
|
|
|
|
|
|
J. Wiesel Cost-Effectiveness of Therapy in Nonatrial Fibrillation Ann Intern Med, December 21, 1999; 131(12): 979 - 979. [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart and J. L. Halperin Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention Ann Intern Med, November 2, 1999; 131(9): 688 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 What Is the Most Cost-Effective Treatment for Nonvalvular Atrial Fibrillation? Journal Watch Cardiology, June 11, 1999; 1999(611): 2 - 2. [Full Text]
|
|
|
|
|
|
S. G. Pauker and M. H. Eckman Finding What You Seek: Analyzing Therapies for Nonvalvular Atrial Fibrillation Ann Intern Med, April 20, 1999; 130(8): 690 - 691. [Full Text] [PDF]
|
|
Article
